12:00 AM
 | 
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

STA-9090: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 15 evaluable patients showed that twice-weekly IV STA-9090 produced 9 cases of stable disease and 2 cases of hematologic...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >